Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 6/20 | 0.62 |
| ▸ | HTR7 | P34969 | 4/20 | 0.56 |
| ▸ | HTR6 | P50406 | 3/20 | 0.56 |
| ▸ | HTR1A | P08908 | 3/20 | 0.56 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.56 |
| ▸ | HTR3B | O95264 | 3/20 | 0.56 |
| ▸ | HTR3A | P46098 | 3/20 | 0.56 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.56 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.56 |
| ▸ | HTR2A | P28223 | 2/20 | 0.56 |
| ▸ | HTR5A | P47898 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | NCF1 | P14598 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | HTR1D | P28221 | 1/20 | 0.56 |
| ▸ | HTR1B | P28222 | 1/20 | 0.56 |
| ▸ | MTOR | P42345 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15834279 | 0.84 | ADRB1 (0.75) | ADRB1HTR7HTR6HTR1AHTR3E | |
| SCHEMBL30350850 | 0.80 | KEAP1 (0.54) | TSHRHSD17B10KDM4EALDH1A1HPGD | |
| SCHEMBL19510747 | 0.80 | KEAP1 (0.54) | TSHRHSD17B10KDM4EALDH1A1HPGD | |
| SCHEMBL17276365 | 0.78 | ADRB1 (0.67) | ADRB1HTR7HTR6HTR1AHTR3E | |
| SCHEMBL22652955 | 0.78 | ADRB1 (0.67) | ADRB1HTR7HTR6HTR1AHTR3E | |
| SCHEMBL172953 | 0.78 | KEAP1 (0.57) | HTR6TSHRLMNAALDH1A1HPGD | |
| SCHEMBL29446047 | 0.77 | ADRB1 (1.00) | ADRB1HTR7HTR6HTR1AHTR3E | |
| SCHEMBL5785574 | 0.77 | ADRB1 (1.00) | ADRB1HTR7HTR6HTR1AHTR3E | |
| SCHEMBL16752537 | 0.77 | ADRB1 (0.64) | ADRB1HTR7HTR6HTR1AHTR3E | |
| SCHEMBL15834278 | 0.77 | ADRB1 (0.64) | ADRB1HTR7HTR6HTR1AHTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1147216-B1 | RESORUFIN DERIVATIVES AS SUBSTRATES FOR CYP3A4 | SMITHKLINE BEECHAM PLC (GB) | 2004-09-08 | — | — | EP | claimed |
| US-20260070907-A1 | FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | UNIV TEMPLE (US) | 2026-03-12 | — | — | US | disclosed |
| US-12503458-B2 | 5-hydroxytryptamine receptor 7 activity modulators and their method of use | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2025-12-23 | — | — | US | disclosed |
| US-20240425487-A1 | NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2024-12-26 | — | — | US | disclosed |
| US-11897870-B2 | 5-hydroxytryptamine receptor 7 activity modulators and their method of use | Temple University-Of The Commonwealth System Higher Education (US) | 2024-02-13 | — | — | US | disclosed |
| US-20220133713-A1 | SIGMA-2 RECEPTOR BINDERS AND THEIR METHOD OF USE | Temple University--of the Commonwealth System of Higher Education | 2022-05-05 | — | — | US | disclosed |
| US-20220133713-A1 | SIGMA-2 RECEPTOR BINDERS AND THEIR METHOD OF USE | Temple University--of the Commonwealth System of Higher Education | 2022-05-05 | — | — | US | disclosed |
| EP-3738955-A1 | NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE | Temple University Of The Commonwealth System Of Higher Education (US) | 2020-11-18 | — | — | EP | disclosed |
| US-20200317648-A1 | NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2020-10-08 | — | — | US | disclosed |
| US-20200317648-A1 | NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2020-10-08 | — | — | US | disclosed |
| US-20160016941-A1 | NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2016-01-21 | — | — | US | disclosed |
| US-20160016941-A1 | NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2016-01-21 | — | — | US | disclosed |
| EP-2970223-A1 | NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE | Temple University Of The Commonwealth System Of Higher Education (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014164756-A1 | NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2014-10-09 | — | — | WO | disclosed |
| US-20110118464-A1 | HALOGENATED XANTHINE DERIVATIVES AND PRECURSORS THEREOF FOR ANTI-CANCER AND ANTI-METASTASIS ACTIVITY AND PREPARING METHOD THEREOF | KAOHSIUNG MEDICAL UNIVERSITY | 2011-05-19 | — | — | US | disclosed |
| US-7524874-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-20050267163-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-12-01 | — | — | US | disclosed |
| US-6329389-B1 | HETEROCYCLIC AMINES AND DERIVATIVES, SOMATOSTATIN AND ANTIDIABETIC AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-12-11 | — | — | US | disclosed |
| EP-0244176-A2 | Thienopyrimidine-2,4-dione derivatives and intermediates thereof | ORTHO PHARMACEUTICAL CORPORATION (US) | 1987-11-04 | — | — | EP | disclosed |
| EP-0204265-A1 | N-Phenyl-4-phenyl-1-piperazine carboxamidines and related compounds as antiarrhythmic agents | LABORATOIRES SYNTEX S.A. (FR) | 1986-12-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503458-B2 | 5-hydroxytryptamine receptor 7 activity modulators and their method of use | HTR7, HTR5A, HTR6 | ADRB1 79/4885HTR7 1/4885HTR6 3/4885 |
| US-20200317648-A1 | NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE | HTR7, HTR6, HTR5A | ADRB1 95/4885HTR7 1/4885HTR6 2/4885 |
| US-20220133713-A1 | SIGMA-2 RECEPTOR BINDERS AND THEIR METHOD OF USE | SIGMAR1, TMEM97, OPRL1 | ADRB1 16/4885HTR7 68/4885HTR6 77/4885 |
| US-20260070907-A1 | FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | HTR7, HTR2C, HTR5A | ADRB1 89/4885HTR7 1/4885HTR6 15/4885 |
| US-20110118464-A1 | HALOGENATED XANTHINE DERIVATIVES AND PRECURSORS THEREOF FOR ANTI-CANCER AND ANTI-METASTASIS ACTIVITY AND PREPARING METHOD THEREOF | TK1, XDH, KYAT1 | ADRB1 527/4885HTR7 2141/4885HTR6 3272/4885 |
| US-11897870-B2 | 5-hydroxytryptamine receptor 7 activity modulators and their method of use | HTR7, HTR5A, HTR6 | ADRB1 79/4885HTR7 1/4885HTR6 3/4885 |
| US-20240425487-A1 | NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE | HTR7, HTR6, HTR5A | ADRB1 95/4885HTR7 1/4885HTR6 2/4885 |
| US-20050267163-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | ADRB1 218/4885HTR7 120/4885HTR6 133/4885 |
| US-20160016941-A1 | NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE | HTR7, HTR6, HTR5A | ADRB1 95/4885HTR7 1/4885HTR6 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.